Literature DB >> 23607306

Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A.

H Pergantou1, I Varela, O Moraloglou, M Economou, K Spanou, Z Kapsimali, N Constantinidou, H Platokouki.   

Abstract

Human Leucocyte Antigen (HLA) alleles, cytokine polymorphisms and the type of factor VIII (FVIII) gene mutation are among predisposing factors for inhibitors (inh) development in children with severe haemophilia A (HA). The aim was to investigate the correlations among (i) FVIII gene intron-22 inversion, (ii) HLA alleles and haplotypes and (iii) certain cytokine polymorphisms, with the risk for FVIII inhibitors development in 52 Greek severe HA children, exclusively treated with recombinant concentrates. We performed Long-Range PCR for detection of intron-22 inversion and PCR-SSP, PCR-SSO for genotyping of HLA-A, B, C, DRB1, DQB1 alleles and also for cytokine polymorphisms of TNF-α, TGF-β1, IL-10, IL-6 and IFN-γ. Chi-squared test and Fischer's exact test were used for statistical analysis. A total of 28 children had developed inhibitors (Group I), 71.4% high responding, while 24 had not (Group II). No statistically increased intron-22 inversion prevalence was found in Group I compared with Group II (P = 0.5). Comparison of HLA allele frequencies between the two groups showed statistically significant differences in the following genotypes (i) promoting inhibitors development: DRB1*01(P = 0.014), DRB1*01:01(P = 0.011) and DQB1*05:01 (P = 0.005) and (ii) possibly protecting from inhibitors development: DRB1*11 (P = 0.011), DRB1*11:01 (P = 0.031), DQB1*03 (P = 0.004) and DQB1*03:01 (P = 0.014). Analysis of cytokines revealed a higher incidence of inhibitor detection only in homozygotes of the haplotypes ACC and ATA for IL-10 polymorphisms (P = 0.05). There is evidence that HLA alleles and cytokine polymorphisms play an important role in FVIII inh development. On the contrary, no statistically significant results were obtained for intron-22 inversion and its impact on FVIII inhibitors formation.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  FVIII inhibitors; HLA alleles; cytokines polymorphisms; severe Haemophilia A

Mesh:

Substances:

Year:  2013        PMID: 23607306     DOI: 10.1111/hae.12168

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

Review 1.  FVIII inhibitors: pathogenesis and avoidance.

Authors:  Jan Astermark
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

2.  Genome-Wide Association Study and Gene-Based Analysis of Participants With Hemophilia A and Inhibitors in the My Life, Our Future Research Repository.

Authors:  Samuel Lessard; Chunla He; Deepak K Rajpal; Katherine Klinger; Christine Loh; Tim Harris; Jennifer Dumont
Journal:  Front Med (Lausanne)       Date:  2022-06-23

3.  B cell-activating factor modulates the factor VIII immune response in hemophilia A.

Authors:  Bhavya S Doshi; Jyoti Rana; Giancarlo Castaman; Mostafa A Shaheen; Radoslaw Kaczmarek; John Ss Butterfield; Shannon L Meeks; Cindy Leissinger; Moanaro Biswas; Valder R Arruda
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

4.  Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Authors:  Delphine Bachelet; Thilo Albert; Cyprien Mbogning; Signe Hässler; Yuan Zhang; Stephan Schultze-Strasser; Yohann Repessé; Julie Rayes; Anna Pavlova; Behnaz Pezeshkpoor; Kerstin Liphardt; Julie E Davidson; Agnès Hincelin-Méry; Pierre Dönnes; Sébastien Lacroix-Desmazes; Christoph Königs; Johannes Oldenburg; Philippe Broët
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

5.  Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A.

Authors:  Silvia Spena; Andrea Cairo; Emanuela Pappalardo; Marcin M Gorski; Isabella Garagiola; Shermarke Hassan; Roberta Gualtierotti; Flora Peyvandi
Journal:  Haemophilia       Date:  2022-02-19       Impact factor: 4.263

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.